Repligen Plans NDA for Imaging Agent on Positive Phase III Data
By Staff Reports
Tuesday, March 15, 2011
Repligen Corp. reported that its imaging agent RG1068, a synthetic human secretin, showed statistically significant improvements in detecting pancreatic disease via magnetic resonance imaging, and the Waltham, Mass.-based firm plans to meet with the FDA to discuss a new drug application filing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.